News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karo Bio AB Ends Spin Off Plans as Cholesterol Drug is Terminated



2/15/2012 8:25:08 AM

Sweden's Karo Bio has pulled the plug on its late-stage cholesterol compound eprotirome and abandoned plans to spin off its preclinical operations. The firm is terminating the Phase III programme on eprotirome, a thyroid hormone analogue which could lower ‘bad’ cholesterol levels in patients already taking statins, after an animal study demonstrated unwanted effects following long-term exposure. Specifically, damage to cartilage was seen in dogs that were given eprotirome for up to 12 months. The cartilage damage was apparent only after a year's exposure and occurred in all animals treated with high doses but was also seen in the lower dose groups. The control animals displayed no damage.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES